• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases.间充质干细胞在治疗两种类型糖尿病及相关疾病中的治疗潜力。
J Diabetes Metab Disord. 2020 Oct 17;19(2):1979-1993. doi: 10.1007/s40200-020-00647-5. eCollection 2020 Dec.
2
Stem cell therapy to cure type 1 diabetes: from hype to hope.干细胞疗法治疗 1 型糖尿病:从炒作到希望。
Stem Cells Transl Med. 2013 May;2(5):328-36. doi: 10.5966/sctm.2012-0116. Epub 2013 Apr 9.
3
Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes.间充质干细胞:1型糖尿病的干细胞治疗前景
Diabetes Metab. 2009 Apr;35(2):85-93. doi: 10.1016/j.diabet.2008.10.003. Epub 2009 Feb 20.
4
Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus.干细胞疗法正成为治疗1型糖尿病的关键手段。
Cytotherapy. 2016 Sep;18(9):1077-86. doi: 10.1016/j.jcyt.2016.06.006. Epub 2016 Jul 14.
5
Human Induced Pluripotent Stem Cells in the Curative Treatment of Diabetes and Potential Impediments Ahead.人类诱导多能干细胞在糖尿病治疗中的应用及潜在障碍
Adv Exp Med Biol. 2019;1144:25-35. doi: 10.1007/5584_2018_305.
6
Mesenchymal stem cells moderate immune response of type 1 diabetes.间充质干细胞调节1型糖尿病的免疫反应。
Cell Tissue Res. 2017 May;368(2):239-248. doi: 10.1007/s00441-016-2499-2. Epub 2016 Oct 10.
7
Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties.新诊断的1型糖尿病患者的多能间充质基质细胞在体外和体内均表现出保留的免疫调节特性。
Stem Cell Res Ther. 2016 Jan 18;7:14. doi: 10.1186/s13287-015-0261-4.
8
Mesenchymal Stem Cell Therapy for Treating the Underlying Causes of Diabetes Mellitus and Its Consequences.间充质干细胞治疗糖尿病及其并发症的潜在病因。
Curr Stem Cell Res Ther. 2024;19(5):662-668. doi: 10.2174/1574888X18666230411111320.
9
A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus.临床试验综述:1型和2型糖尿病中的间充质干细胞移植疗法
Am J Stem Cells. 2018 Oct 1;7(4):82-93. eCollection 2018.
10
The roles of mesenchymal stem cell-derived exosomes in diabetes mellitus and its related complications.间充质干细胞衍生的外泌体在糖尿病及其相关并发症中的作用。
Front Endocrinol (Lausanne). 2022 Oct 21;13:1027686. doi: 10.3389/fendo.2022.1027686. eCollection 2022.

引用本文的文献

1
Advanced therapy to cure diabetes: mission impossible is now possible?治愈糖尿病的先进疗法:“不可能完成的任务”现在有可能实现吗?
Front Cell Dev Biol. 2024 Nov 19;12:1484859. doi: 10.3389/fcell.2024.1484859. eCollection 2024.
2
The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells.糖尿病对间充质干细胞分化为胰岛素分泌细胞的影响。
Biol Res. 2024 May 2;57(1):20. doi: 10.1186/s40659-024-00502-4.
3
Micro RNA based MSC EV engineering: Targeting the BMP2 cascade for bone repair.基于微小RNA的间充质干细胞外泌体工程:靶向骨形态发生蛋白2级联反应促进骨修复
Front Cell Dev Biol. 2023 Feb 8;11:1127594. doi: 10.3389/fcell.2023.1127594. eCollection 2023.

本文引用的文献

1
Mesenchymal Stem Cell Derived Extracellular Vesicles Ameliorate Kidney Injury in Aristolochic Acid Nephropathy.间充质干细胞衍生的细胞外囊泡改善马兜铃酸肾病中的肾损伤。
Front Cell Dev Biol. 2020 Mar 24;8:188. doi: 10.3389/fcell.2020.00188. eCollection 2020.
2
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition.2019 年全球及各区域糖尿病患病率估算值及 2030 年和 2045 年预测值:国际糖尿病联盟糖尿病地图集(第 9 版)的结果。
Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.
3
Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes.利拉鲁肽联合人脐带间充质干细胞移植通过调控 ASK1/JNK/BAX 通路抑制 2 型糖尿病大鼠胰岛β细胞凋亡。
Diabetes Metab Res Rev. 2020 Feb;36(2):e3212. doi: 10.1002/dmrr.3212. Epub 2019 Sep 2.
4
Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy.干细胞衍生的细胞外囊泡抑制和逆转糖尿病肾病小鼠模型中的纤维化进展。
Sci Rep. 2019 Mar 14;9(1):4468. doi: 10.1038/s41598-019-41100-9.
5
Potential of Allogeneic Adipose-Derived Stem Cell-Hydrogel Complex for Treating Diabetic Foot Ulcers.异体脂肪来源干细胞-水凝胶复合物治疗糖尿病足溃疡的潜力。
Diabetes. 2019 Apr;68(4):837-846. doi: 10.2337/db18-0699. Epub 2019 Jan 24.
6
Salidroside-Pretreated Mesenchymal Stem Cells Enhance Diabetic Wound Healing by Promoting Paracrine Function and Survival of Mesenchymal Stem Cells Under Hyperglycemia.红景天苷预处理间充质干细胞通过促进高糖环境下间充质干细胞的旁分泌功能和存活来增强糖尿病创面愈合。
Stem Cells Transl Med. 2019 Apr;8(4):404-414. doi: 10.1002/sctm.18-0143. Epub 2019 Jan 9.
7
Adipose stem cells and their paracrine factors are therapeutic for early retinal complications of diabetes in the Ins2 mouse.脂肪干细胞及其旁分泌因子可治疗 Ins2 小鼠糖尿病的早期视网膜并发症。
Stem Cell Res Ther. 2018 Nov 21;9(1):322. doi: 10.1186/s13287-018-1059-y.
8
Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application.基于间充质干细胞的免疫调节:特性与临床应用
Stem Cells Int. 2018 Jun 14;2018:3057624. doi: 10.1155/2018/3057624. eCollection 2018.
9
Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research.干细胞治疗糖尿病足溃疡:临床前和临床研究综述。
Stem Cell Res Ther. 2018 Jul 11;9(1):188. doi: 10.1186/s13287-018-0938-6.
10
Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?1型糖尿病的药物治疗——胰岛素及其他?
Int J Endocrinol Metab. 2017 Nov 20;16(1):e13008. doi: 10.5812/ijem.13008. eCollection 2018 Jan.

间充质干细胞在治疗两种类型糖尿病及相关疾病中的治疗潜力。

Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases.

作者信息

Goenka Vidul, Borkar Tanhai, Desai Aska, Das Raunak Kumar

机构信息

School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu India.

Centre for Biomaterials, Cellular and Molecular Theranostics, Vellore Institute of Technology, Vellore, Tamil Nadu India.

出版信息

J Diabetes Metab Disord. 2020 Oct 17;19(2):1979-1993. doi: 10.1007/s40200-020-00647-5. eCollection 2020 Dec.

DOI:10.1007/s40200-020-00647-5
PMID:33520872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7843693/
Abstract

Diabetes mellitus is a common lifestyle disease which can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus. While both result in hyperglycemia due to lack of insulin action and further associated chronic ailments, there is a marked distinction in the cause for each type due to which both require a different prophylaxis. As observed, type 1 diabetes is caused due to the autoimmune action of the body resulting in the destruction of pancreatic islet cells. On the other hand, type 2 diabetes is caused either due to insulin resistance of target cells or lack of insulin production as per physiological requirements. Attempts to cure the disease have been made by bringing drastic changes in the patients' lifestyle; parenteral administration of insulin; prescription of drugs such as biguanides, meglitinides, and amylin; pancreatic transplantation; and immunotherapy. While these attempts cause a certain degree of relief to the patient, none of these can cure diabetes mellitus. However, a new treatment strategy led by the discovery of mesenchymal stem cells and their unique immunomodulatory and multipotent properties has inspired therapies to treat diabetes by essentially reversing the conditions causing the disease. The current review aims to enumerate the role of various mesenchymal stem cells and the different approaches to treat both types of diabetes and its associated diseases as well.

摘要

糖尿病是一种常见的生活方式疾病,可分为1型糖尿病和2型糖尿病。虽然两者都因胰岛素作用缺乏以及进一步相关的慢性疾病而导致高血糖,但每种类型的病因有明显区别,因此两者需要不同的预防措施。如所观察到的,1型糖尿病是由于身体的自身免疫作用导致胰岛细胞被破坏而引起的。另一方面,2型糖尿病要么是由于靶细胞的胰岛素抵抗,要么是由于生理需求胰岛素分泌不足引起的。人们试图通过大幅改变患者生活方式、胃肠外注射胰岛素、开双胍类、格列奈类和胰淀素等药物、胰腺移植以及免疫疗法来治愈这种疾病。虽然这些尝试能给患者带来一定程度的缓解,但这些方法都无法治愈糖尿病。然而,由间充质干细胞的发现及其独特的免疫调节和多能特性引领的一种新的治疗策略激发了通过从根本上逆转导致该疾病的状况来治疗糖尿病的疗法。本综述旨在列举各种间充质干细胞的作用以及治疗两种类型糖尿病及其相关疾病的不同方法。